Foamix Gains Five Additional US Patents


The United States Patent and Trademark Office (USPTO) issued Foamix five new patents covering its technologies.

Foamix, a specialty pharmaceutical company, focuses on developing and commercializing proprietary topical foams. The additional five patents raises Foamix's number to 25 United States patents, 61 issued worldwide, and 126 patents pending.

"These new patents strengthen our position as the leading company worldwide specializing in developing foam based pharmaceutical products," said Dov Tamarkin, Chief Executive Officer of Foamix, Ltd.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free